Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Authors' conclusion
Utilization of GLDs doubled, and associated costs tripled over the past 11 years, with no sign of either utilization or costs plateauing, predominantly due to increased GLP-1RA and SGLT2 inhibitor prescribing.
Study context
- Population
- Non-insulin GLD prescriptions in the Australian Pharmaceutical Benefits Scheme (PBS) dataset, 2013–2023
- Participants
- 118,727,494 GLD prescriptions
- Exposure
- SGLT2 inhibitors vs GLP-1RAs vs Dipeptidyl peptidase-4 inhibitor vs Metformin vs sulphonylurea vs glitazone vs acarbose
- Outcome
- Annual number of GLD prescriptions dispensed, accounting for T2D prevalence, and healthcare system costs, adjusted for inflation
- Follow-up
- 2013 to 2023
Methodological detailspopulation-based, inflation-adjusted costs
- Population-based
- Inflation-adjusted costs
Main finding
As reported in the abstract
GLD utilization
- Total GLD prescriptions, 2013 to 2023
- 6.4 million to 15.6 million
- Average annual percent increase in GLD utilization
- 8.1%
- Average annual increase in T2D prevalence
- 1.8%
- GLP-1 RA share of utilization vs share of costs
- 11.7% vs 35%
Observational data: associations, not effects.
Original publication
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023. Diabetes Obes Metab. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →